Skip to main contentSkip to navigation
Sirius Investors
Talis Biomedical Corporation

Talis Biomedical Corporation

TLIS
OTCHealthcare

Talis Biomedical Corporation (TLIS) Investment Research Dashboard

About Talis Biomedical Corporation (TLIS) stock analysis

Get live TLIS stock price $2.84, comprehensive Talis Biomedical Corporation stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time TLIS stock data and investment insights.

2.84
0.00%Today
Market Cap
5.18M
Volume
1.68K
52W High
2.84
52W Low
1.04

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologi...

Company Information

CEO
Rebecca Markovich
Sector
Healthcare
Industry
Medical - Devices
Employees
99

Contact Information

Address
230 Constitution Drive
Country
US

Investment Analysis & Business Insights

Healthcare
Medical - Devices

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.32)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Talis Biomedical Corporation shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Talis Biomedical Corporation
  • Investors should consider how Talis Biomedical Corporation fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

5.18M

P/E Ratio (TTM)

-0.10

Beta

1.32

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

80/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+5.7%+6.1%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
86/100⭐⭐⭐⭐⭐
Healthcare+0.7%+3.3%+3.5%24.1
80/100⭐⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
56/100⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
56/100⭐⭐⭐⭐
Real Estate-0.5%-0.1%-1.6%29.2
43/100⭐⭐⭐
Energy-2.1%-5.8%-5.1%19.1
39/100⭐⭐
Utilities-1.0%-3.0%-5.9%26.8
28/100⭐⭐
Industrials+0.6%+1.7%-11.2%30.1
26/100⭐⭐
Consumer Cyclical+0.5%-0.4%-6.3%43.0
21/100
Technology+0.6%-2.3%-9.6%40.7
17/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.